Our Facilities

Seamless Global Production with Personalized Care

At ProBio, we offer both the personalized care of a small CDMO and the resources of a global organization. Our American and Chinese facilities enable seamless, simultaneous drug production, keeping your programs efficient and consistent with one trusted partnership.

Hopewell, New Jersey, USA

ProBio’s New Jersey facility is a cutting-edge, 128,000-square-foot gene therapy production site designed to meet the growing demand for advanced therapeutics. Officially opened in 2024, this facility focuses on providing high-quality GMP manufacturing for gene therapies, including viral vector production. With a strong emphasis on innovation and efficiency, the New Jersey facility plays a pivotal role in ProBio’s global manufacturing network, offering scalable solutions to accelerate therapeutic development.

New Jersey, USA

Services

  • Plasmid process development (PD)
  • Plasmid GMP production (available Q1 2025)
  • Viral vector process development and GMP production for AAV (available Q3 2025)
  • Viral vector process development and GMP production for LVV (available Q3 2026)
  • Drug Product Manufacturing, AAV Fill & Finish